A detailed history of Concord Wealth Partners transactions in Quest Diagnostics Inc stock. As of the latest transaction made, Concord Wealth Partners holds 16 shares of DGX stock, worth $2,193. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16
Previous 18 11.11%
Holding current value
$2,193
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$137.09 - $137.09 $274 - $274
-2 Reduced 11.11%
16 $2,000
Q4 2023

Apr 30, 2024

SELL
$120.62 - $141.12 $2,171 - $2,540
-18 Reduced 50.0%
18 $2,000
Q4 2023

Feb 05, 2024

SELL
$120.62 - $141.12 $2,171 - $2,540
-18 Reduced 50.0%
18 $2,000
Q3 2023

Apr 30, 2024

BUY
$121.86 - $144.92 $2,193 - $2,608
18 Added 100.0%
36 $4,000
Q2 2023

Aug 07, 2023

BUY
$130.56 - $146.84 $2,350 - $2,643
18 Added 100.0%
36 $5,000
Q1 2023

Apr 26, 2023

SELL
$131.53 - $155.76 $4,472 - $5,295
-34 Reduced 65.38%
18 $2,000
Q4 2022

Jan 27, 2023

BUY
$123.31 - $157.26 $6,412 - $8,177
52 New
52 $8,000
Q2 2022

Aug 04, 2022

SELL
$127.07 - $145.39 $131,898 - $150,914
-1,038 Reduced 89.48%
122 $16,000
Q1 2022

Apr 20, 2022

BUY
$129.09 - $164.35 $1,807 - $2,300
14 Added 1.22%
1,160 $159,000
Q4 2021

Jan 21, 2022

BUY
$140.36 - $173.01 $106,673 - $131,487
760 Added 196.89%
1,146 $198,000
Q3 2021

Nov 09, 2021

SELL
$132.95 - $158.0 $79,770 - $94,800
-600 Reduced 60.85%
386 $56,000
Q2 2021

Jul 29, 2021

BUY
$126.66 - $141.48 $15,072 - $16,836
119 Added 13.73%
986 $130,000
Q1 2021

May 13, 2021

BUY
$114.63 - $133.34 $97,550 - $113,472
851 Added 5318.75%
867 $111,000
Q4 2020

Feb 16, 2021

BUY
$112.7 - $128.05 $1,803 - $2,048
16 New
16 $2,000

Others Institutions Holding DGX

About QUEST DIAGNOSTICS INC


  • Ticker DGX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 113,887,000
  • Market Cap $15.6B
  • Description
  • Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers dia...
More about DGX
Track This Portfolio

Track Concord Wealth Partners Portfolio

Follow Concord Wealth Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

News

Stay updated on Concord Wealth Partners with notifications on news.